I-05 Floris Fauchet Impact of maternal zidovudine infusions at labor on fetus: a population pharmacokinetic study Wednesday 10:20-11:50 |
I-08 Aline Fuchs Impact of medication adherence measurement on antiretroviral drug pharmacokinetics: A retrospective cohort study in HIV patients followed by therapeutic drug monitoring and taking part in a medication-adherence enhancing program Wednesday 10:20-11:50 |
I-16 Sandra Gil Modeling the Postantifungal Effect of Anidulafungin Against Candida Wednesday 10:20-11:50 |
I-50 Ron Keizer Expected effectiveness of reduced-dose efavirenz Wednesday 10:20-11:50 |
I-51 David Khan Evaluation of Mechanism Based PKPD Model for Antibiotics Wednesday 10:20-11:50 |
II-03 Laure Lalande Population modelling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs Wednesday 15:10-16:30 |
II-04 Cédric Laouenan Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir and Peg-IFN during triple therapy in treatment-experienced HCV infected cirrhotic patients Wednesday 15:10-16:30 |
II-27 Iris Minichmayr Target site pharmacokinetics of doripenem in plasma and interstitial space fluid of peripheral tissues Wednesday 15:10-16:30 |
II-40 Ingrid Ottevaere Population pharmacokinetics of ALX-0171, an inhaled Respiratory Syncytial Virus (RSV) neutralizing Nanobody. Wednesday 15:10-16:30 |
II-52 Gauri Rao Characterization of Oseltamivir Carboxylate (OC) Disposition using a Reduced Population (POP) Pharmacokinetic (PK) Model Wednesday 15:10-16:30 |
II-60 Adedeji Majekodunmi Mixed Effect Modelling in HCV-HIV co-infected Children Wednesday 15:10-16:30 |
III-07 Natalia Aniceto Population Pharmacokinetics-Pharmacogenetics of Efavirenz using Non-Linear Mixed Effects Modeling and Bayesian Estimation Thursday 10:05-11:30 |
III-08 Manel Aouri Population pharmacokinetics and pharmacogenetics analysis of Rilpivirine in HIV-1 infected individuals Thursday 10:05-11:30 |
III-09 Eduardo Asín-Prieto Population Pharmacokinetics of Daptomycin in Critically Ill Patients Thursday 10:05-11:30 |
III-12 Ana Bastos Modeling and simulation of temocillin (TMO) in patients with end stage renal disease undergoing haemodialysis Thursday 10:05-11:30 |
III-16 Andrzej Bienczak Population Pharmacokinetic Analysis of Efavirenz in African Children using mixture modelling to describe clearance multimodality. Thursday 10:05-11:30 |
III-28 Jantine Brussee Modelling and simulation of the effect of L-arginine adjunctive therapy on vascular function in patients with moderately severe malaria Thursday 10:05-11:30 |
III-33 Aziz Chaouch Population pharmacokinetics of oral voriconazole patients undergoing cataract surgery: modelling concentrations in plasma and in the aqueous humour Thursday 10:05-11:30 |
III-35 Chunli Chen Population pharmacokinetic-pharmacodynamic modelling of rifampicin treatment response in a tuberculosis acute mouse model Thursday 10:05-11:30 |
III-47 Paola Coppola Pharmacokinetic assessment of prulifloxacin in patients with renal impairment using population pharmacokinetics modelling and simulations Thursday 10:05-11:30 |
III-52 Paolo Denti Population pharmacokinetics of cefazolin in children undergoing elective cardiac surgery Thursday 10:05-11:30 |
IV-15 Konstantina Soulele A population pharmacokinetic study of fluticasone/salmeterol in healthy subjects using two different dry powder inhalers Thursday 15:15-16:40 |
IV-16 Christine Staatz A survey of intravenous tobramycin monitoring and dosage adjustment practice in cystic fibrosis patients in Australia and the United Kingdom Thursday 15:15-16:40 |
IV-33 Elodie Valade Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics Thursday 15:15-16:40 |
IV-36 Coen van Hasselt Development of an integrated model-based framework to support clinical development of antibiotics Thursday 15:15-16:40 |
IV-39 Rob van Wijk Challenges in the evaluation of the preclinical dosing rationale for tuberculosis treatment Thursday 15:15-16:40 |
IV-52 Hinojal Zazo Gómez PK/PD modelling and simulation of stavudine nanoparticles in HIV patients Thursday 15:15-16:40 |